Earnings call transcript: MSAB posts record Q3 2026 as profit jumps 57%

MSAB reported record Q3 2026 results: net sales rose 19.4% year over year to SEK 175 million and EBIT increased 57% to SEK 72 million, with gross margin at 95%. Annual contract value grew 16% to SEK 460 million, while management was positive on Q4 and 2027 and said a delayed large deal is expected to close in Q4; it also plans continued investment and is more actively considering acquisitions. Shares were down 0.92% to $108 in the latest data, and management cautioned that large-deal timing can make quarterly results volatile.

Analysis

The strongest forward signal is not the quarter’s EBIT growth but whether ACV converts into durable revenue: reported profit benefited from seasonal cost reductions and a holiday-pay reversal, so annualizing the margin step-up would overstate run-rate earnings. The upgrade runway is real but conditional: only about one-fifth of the installed base has moved to XRY Pro, and management cites roughly 4x pricing versus legacy products; conversion pace, customer retention and realized contract pricing matter more than the theoretical uplift. New sales rising as a share of revenue is encouraging, but also makes quarterly results more exposed to lumpy procurement.

Over the next 1–3 months, the delayed U.S. contract is a binary timing catalyst, not evidence of a broad U.S. recovery. A close would support Q4; another slip would expose the quarter’s deal concentration. Over 6–18 months, product investment and potential frontline software broaden the opportunity, while military demand has long sales cycles. Management’s confidence on margins should be tested against the stated higher investment plans; AI-driven development efficiencies remain a claim, not yet demonstrated economics.

The market’s muted response near the stock’s high suggests much of the strong execution may already be reflected in price. The CEO’s product and pricing claims versus Cellebrite are not independent evidence of share gains; avoid inferring a short thesis in CLBT without its own results and valuation context. The contrarian opportunity is to buy evidence of sustained ACV-to-revenue conversion on weakness, rather than chase a record quarter with a temporarily favorable cost base.

Key Decisions for Investors

• Do not chase MSAB.B immediately. Consider a staged long on a pullback, contingent on the delayed U.S. contract closing and continued ACV growth; the near-high price and seasonal EBIT benefit make the near-term risk/reward less attractive.
• Track Q4 and the next reporting period for contract conversion, new-sales mix, churn, and normalized operating costs. Falsify the long thesis if the delayed deal slips again, ACV growth materially decelerates, or investment spending erodes EBIT margin despite revenue growth.
• Keep CLBT as a relative-performance watch, not an automatic short against MSAB.B. Reassess only after comparable results establish whether MSAB.B is actually taking share rather than benefiting from deal timing or competitor-specific disruption.
• Treat acquisitions and AI efficiency as optionality, not base-case value, until MSAB.B discloses a transaction or measurable cost/productivity outcomes.